Skip to main content
LUMOS DIAGNOSTICS HOLDINGS LIMITED logo

LUMOS DIAGNOSTICS HOLDINGS LIMITED — Investor Relations & Filings

Ticker · LDX ISIN · AU0000157091 LEI · 529900M15QXKTRG8YS81 ASX Manufacturing
Open in API
Filings indexed 521 across all filing types
Latest filing 2026-05-19 Share Issue/Capital Cha…
Country AU Australia
Listing ASX LDX

About LUMOS DIAGNOSTICS HOLDINGS LIMITED

https://lumosdiagnostics.com

Lumos Diagnostics Holdings Limited specializes in the development, manufacturing, and commercialization of rapid point-of-care (POC) diagnostic solutions. The company focuses on improving patient outcomes and supporting antimicrobial stewardship through proprietary diagnostic tests and digital reader platforms. A primary product, FebriDx, is a rapid test designed to differentiate between viral and bacterial respiratory infections within minutes. Beyond its internal product pipeline, the company provides comprehensive contract development and manufacturing organization (CDMO) services. These services support third-party partners in the design, development, and large-scale production of lateral flow assays. Lumos integrates advanced reader technology with assay chemistry to deliver integrated diagnostic systems for clinical and industrial applications.

Recent filings

Filing Released Lang Actions
Section 708A Cleansing Statement 2 pages 319.8KB
Share Issue/Capital Change Classification · 87% confidence The document is an ASX announcement under Section 708A of the Corporations Act confirming the issuance of 5,337,000 fully paid ordinary shares. It is a notification of a new share issue/capital change rather than a full report or earnings release. This aligns with the “Share Issue/Capital Change” category.
2026-05-19 English
Application for quotation of securities - LDX 8 pages 21.7KB
Share Issue/Capital Change Classification · 91% confidence The document is an ASX Listing Rules “Appendix 2A – Application for quotation of securities” announcing the issue of 5,337,000 new ordinary shares relating to the CEO’s FY24 bonus and applying for their quotation. This is a regulatory announcement of a share issuance/capital change. It falls under the Share Issue/Capital Change category.
2026-05-19 English
FebriDx U.S. Rollout and Reimbursement Update 3 pages 390.9KB
Regulatory Filings Classification · 75% confidence The document is an ASX announcement providing an operational update on the U.S. rollout and reimbursement progress for FebriDx®. It does not contain financial statements or earnings figures, nor is it presenting detailed investor slides, nor is it reporting a formal annual or interim report. It is not announcing a vote result or share issue. It is a general corporate disclosure under ASX rules, making it a miscellaneous regulatory announcement. Hence, it falls under the fallback category "Regulatory Filings (RNS)."
2026-05-17 English
FebriDx U.S. Rollout and Reimbursement Update - Amended 4 pages 396.0KB
Regulatory Filings Classification · 82% confidence The document is an ASX market announcement providing a business update on the U.S. rollout and reimbursement progress for FebriDx®; it contains no financial statements, no share issues or votes, no management changes, and no formal report is being published (beyond the announcement itself). It is a standard regulatory update to the stock exchange, falling under general Regulatory Filings (RNS).
2026-05-17 English
FebriDx Paediatric Study Enrolment Milestone Achieved 3 pages 410.3KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement detailing the achievement of a clinical trial milestone and associated grant funding payment under a BARDA agreement. It does not present financial statements, earnings results, management discussion, capital raising (equity/debt) or AGM materials. It is a routine regulatory announcement of an operational development and receipt of grant funds. This falls into the catch-all Regulatory Filings category for miscellaneous public disclosures. Therefore, it should be classified as RNS.
2026-05-13 English
Lumos receives US$0.5m CLIA waiver milestone payment 2 pages 387.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Lumos Diagnostics regarding the receipt of a milestone payment from BARDA for achieving a CLIA waiver for their product FebriDx®. It details the payment amount, contract information, and the significance of the milestone for the company. The text is relatively short (4210 characters) and focuses on a specific financing event related to government funding and milestone payments. There are no financial statements, quarterly or annual results, or detailed management discussion. The content is clearly an update on financing and funding activities rather than a full report or earnings release. Therefore, the document fits best under Capital/Financing Update (CAP).
2026-05-06 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.